Aziyo Biologics Inc - Ordinary Shares - Class A Aktie News

— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) —

Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope's impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product La...

— Innovative approach accelerates new product development and testing — — Innovative approach accelerates new product development and testing —

Elutia Inc. (NASDAQ:ELUT ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Matt Steinberg - FINN Partners Randal Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Matt Park - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia First Quarter 2025...

- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m.

Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the con...

SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time...

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia's Chief Scientific Officer, will participate in Chardan's Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.